Zacks Research Issues Pessimistic Estimate for TEVA Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities researchers at Zacks Research cut their FY2026 EPS estimates for Teva Pharmaceutical Industries in a research note issued to investors on Tuesday, December 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.75 per share for the year, down from their prior forecast of $2.77. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.36 per share.

Several other equities research analysts have also weighed in on the stock. UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Trading Up 1.6 %

TEVA opened at $17.81 on Thursday. The firm’s 50-day simple moving average is $17.54 and its 200-day simple moving average is $17.37. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a twelve month low of $9.35 and a twelve month high of $19.31.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. increased its stake in shares of Teva Pharmaceutical Industries by 141.7% in the 3rd quarter. Franklin Resources Inc. now owns 155,091 shares of the company’s stock valued at $2,674,000 after acquiring an additional 90,920 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Sanctuary Advisors LLC increased its stake in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after purchasing an additional 664 shares in the last quarter. TCW Group Inc. bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $1,286,000. Finally, Geode Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after purchasing an additional 291,124 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.